These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38442452)

  • 21. Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early-stage breast cancer patients who received trastuzumab: Evidence from a real-world study with long-term follow-up.
    Ju J; Gao SL; Wang JY; Sang D; Kang YK; Wang X; Yue J; Shuai Y; Qi YX; Yuan P
    Thorac Cancer; 2024 Feb; 15(6):439-447. PubMed ID: 38185807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.
    Bringolf L; Pestalozzi B; Fink D; Dedes K
    Swiss Med Wkly; 2016; 146():w14393. PubMed ID: 28102883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.
    Yamashiro H; Iwata H; Masuda N; Yamamoto N; Nishimura R; Ohtani S; Sato N; Takahashi M; Kamio T; Yamazaki K; Saito T; Kato M; Lee T; Kuroi K; Takano T; Yasuno S; Morita S; Ohno S; Toi M;
    Breast Cancer; 2020 Jul; 27(4):631-641. PubMed ID: 32060785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
    Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
    Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
    Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
    Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.
    Rier HN; Levin MD; van Rosmalen J; Bos MMEM; Drooger JC; de Jong P; Portielje JEA; Elsten EMP; Ten Tije AJ; Sleijfer S; Jager A
    Oncologist; 2017 Aug; 22(8):901-909. PubMed ID: 28533475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
    Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
    JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
    Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
    Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
    Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
    Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
    Dieci MV; Conte P; Bisagni G; Brandes AA; Frassoldati A; Cavanna L; Musolino A; Giotta F; Rimanti A; Garrone O; Bertone E; Cagossi K; Sarti S; Ferro A; Piacentini F; Maiorana A; Orvieto E; Sanders M; Miglietta F; Balduzzi S; D'Amico R; Guarneri V
    Ann Oncol; 2019 Mar; 30(3):418-423. PubMed ID: 30657852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
    Cho JH; Lim JY; Cho JY
    World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study.
    Kubo M; Kawai M; Kumamaru H; Miyata H; Tamura K; Yoshida M; Ogo E; Nagahashi M; Asaga S; Kojima Y; Kadoya T; Aogi K; Niikura N; Miyashita M; Iijima K; Hayashi N; Yamamoto Y; Imoto S; Jinno H
    Breast Cancer Res Treat; 2019 Dec; 178(3):647-656. PubMed ID: 31451979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society.
    Kim HS; Yoo TK; Park WC; Chae BJ
    Breast Cancer Res Treat; 2020 Apr; 180(2):461-470. PubMed ID: 32020434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
    Earl H; Hiller L; Vallier AL; Loi S; McAdam K; Hughes-Davies L; Rea D; Howe D; Raynes K; Higgins HB; Wilcox M; Plummer C; Mahler-Araujo B; Provenzano E; Chhabra A; Gasson S; Balmer C; Abraham JE; Caldas C; Hall P; Shinkins B; McCabe C; Hulme C; Miles D; Wardley AM; Cameron DA; Dunn JA
    Health Technol Assess; 2020 Aug; 24(40):1-190. PubMed ID: 32880572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
    Moreno-Aspitia A; Hillman DW; Dyar SH; Tenner KS; Gralow J; Kaufman PA; Davidson NE; Lafky JM; Reinholz MM; Lingle WL; Kutteh LA; Carney WP; Dueck AC; Perez EA
    Cancer; 2013 Aug; 119(15):2675-82. PubMed ID: 23744760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer.
    Zhong W; Yang Y; Zhang A; Lin W; Liang G; Ling Y; Zhong J; Yong J; Liu Z; Tian Z; Lin Q; Luo Q; Li Y; Gong C
    Breast Cancer; 2020 Nov; 27(6):1147-1157. PubMed ID: 32780321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
    Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
    Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.